Health Canada approved Imbruvica (ibrutinib) as an oral, once-daily, single-agent targeted therapy for previously untreated patients with active chronic lymphocytic leukemia. This is the fourth Canadian approval for Imbruvica, which is now approved for use in all lines of CLL therapy.
An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.
